Atripla

DRUG12 trials

Conditions

Acquired Immune Deficiency SyndromeHIVHIV InfectionsHIV-1 InfectionHIV-1-infectionHIV-DDIInfection, Human Immunodeficiency Virus I

Phase 1

Interaction With HIV Antiretroviral Agents

CompletedNCT02556268

BayerHIV-DDI

Start: 2016-02-23End: 2016-12-07Updated: 2017-12-06

Phase 2

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

CompletedNCT00752856

University of California, San DiegoHIV Infections

Start: 2008-08-26End: 2014-02-11Updated: 2020-07-22

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT00869557

Gilead SciencesHIV, HIV Infections

Start: 2009-04-30End: 2013-09-30Updated: 2014-06-04

Phase 3

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT01095796

Gilead SciencesHIV, HIV Infections

Start: 2010-03-31End: 2014-09-30Updated: 2015-11-11

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

CompletedNCT01263015

ViiV HealthcareInfection, Human Immunodeficiency Virus I

Start: 2011-02-01End: 2015-12-03Updated: 2018-04-04

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy

CompletedNCT03122262

Professor Francois VenterHIV-1 Infection

Start: 2017-01-16End: 2022-07-29Updated: 2023-02-08

Phase 4

ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial

CompletedNCT00615810

Gilead SciencesHIV Infections

Start: 2008-03-31End: 2010-01-31Updated: 2010-08-02

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

WithdrawnNCT01173510

Community Research Initiative of New EnglandAcquired Immune Deficiency Syndrome, HIV Infections

Start: 2010-08-23End: 2012-10-19Updated: 2017-06-14

Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection

NCT01343225

East Carolina UniversityHIV

Start: 2011-05-31End: 2014-05-31Target: 40Updated: 2011-04-28

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

CompletedNCT01778413

Anna CrucetaHIV

Start: 2013-06-03End: 2015-07-21Updated: 2025-07-18

Sleep and Cognition After Atripla to Stribild Switch

NCT02283060

University of HawaiiHIV

Start: 2014-09-30End: 2016-08-31Target: 30Updated: 2016-03-14

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

TerminatedNCT03532425

University of AlbertaHIV-1-infection

Start: 2018-10-29End: 2020-09-03Updated: 2022-12-14

Southern African Journal of HIV Medicine2025-03-18

Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa

Journal of the International AIDS Society2024-07-013 citations

Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa

British Journal of Clinical Pharmacology2024-02-084 citations

Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV

Pharmacogenetics and Genomics2023-03-063 citations

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial

Clinical Infectious Diseases2022-10-1815 citations

Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Infectious Diseases2022-09-1921 citations

Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens

JAIDS Journal of Acquired Immune Deficiency Syndromes2021-02-2710 citations

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase

Nature Communications2020-12-0181 citations

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.

2020-10-01196 citations

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

New England Journal of Medicine2019-07-24681 citations

Effects on immune system and viral reservoir of a short-cycle antiretroviral therapy in virologically suppressed HIV-positive patients

AIDS2019-02-099 citations

Pharmacokinetic (PK) interaction of fixed-dose combination (FDC) antiretrovirals (ARV) with riociguat (rio)

2018-09-151 citations

A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.

2018-07-018 citations

A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals

PLoS ONE2015-02-0627 citations

Safety and Efficacy of DTG Plus ABC/3TC for Treatment-Naive Patients with HIV

MD Conference Express2014-11-01

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

New England Journal of Medicine2013-11-06862 citations

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

2012-06-01331 citations